Pneumotactix is developing a medicinal enzyme that breaks downs capsular polysaccharide, the protective shield around harmful bacterium. The process has the potential to give the body’s immune system a new advantage in fighting severe illness.
The company’s technology has demonstrated the ability to protect against lethal Streptococcus, or Strep, and their current focus is a strain of Paenibacillus.
Pneumotactix is working to investigate the potential toxicity and immunogenicity of the enzyme and is exploring ways to optimize its production.
Company website: Pneumotactix
Back to companies